Publications by authors named "M Varenna"
Is CRPS-1 a Chronic Disabling Disease? A Long-term, Real-Life Study on Patients Treated With Neridronate.
Clin Med Insights Arthritis Musculoskelet Disord
November 2024
Article Synopsis
- - This study focused on assessing the long-term effects of neridronate treatment on patients with Complex Regional Pain Syndrome type 1 (CRPS-1), a condition that causes severe pain and disability, particularly in the upper limbs.
- - A retrospective analysis included 49 patients who received neridronate infusions, revealing that 93.9% of them experienced a complete resolution of symptoms after an average follow-up of about 4 years, with 77.6% showing no functional limitations.
- - Key factors influencing residual disability post-treatment were found to be younger age and the delay between the onset of the disease and the start of treatment, suggesting that earlier intervention may lead to better recovery outcomes.
Hypophosphatasia (HPP) is a rare disorder of the bone metabolism, characterized by genetically determined low alkaline phosphatase (ALP) activity. Low ALP may also be observed in some common causes of bone fragility, such as in osteoporosis treated with antiresorptive drugs. This study aimed to verify whether differences in bone turnover markers (BTMs) could help differentiate adult patients with HPP from those with osteoporosis undergoing antiresorptive treatment.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates serum levels of bone turnover markers and Wnt signaling in patients with complex regional pain syndrome type 1 (CRPS-1) before treatment.
- It compares bone turnover marker values (sclerostin, DKK1, CTX-I, P1NP) of 34 CRPS-1 patients with age and sex-matched healthy controls, finding significant differences for P1NP, sclerostin, and DKK1.
- Results suggest that early CRPS-1 is associated with increased bone formation markers and decreased levels of Wnt signaling inhibitors, indicating potential osteocyte dysfunction rather than increased osteoclast activity.
Objective: Fragility fractures (FF) resulting from osteoporosis pose a significant public health challenge in Italy, with considerable socio-health and economic implications. Despite the availability of safe and effective drugs, osteoporosis remains underdiagnosed and undertreated, leaving over 2 million high-risk Italian women without treatment. This paper aims to identify and propose key improvements in the management of osteoporosis, focusing particularly on the critical issues related to the use of anabolic drugs in secondary prevention, according to the current Italian Medicines Agency (AIFA) Note 79.
View Article and Find Full Text PDFIntroduction: This study aims to examine the potential effectiveness of intravenous neridronate (IVNer) on axial involvement in patients with spondyloarthritis (SpA) refractory to non-steroidal anti-inflammatory drugs (NSAIDs) but not eligible for biological disease-modifying antirheumatic drugs (bDMARDs).
Method: Patients with active SpA (BASDAI score ≥ 4) and active sacroiliitis (SI) on MRI (according to ASAS MRI definition), who were NSAID-insufficient responder/intolerant but not eligible for bDMARDs, were retrospectively recruited in a tertiary rheumatology centre between September 2015 and December 2021. IVNer (100 mg) was administered to the patients on days 1, 4, 7, and 10.